These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 115231

  • 1. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract] [Full Text] [Related]

  • 2. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [Abstract] [Full Text] [Related]

  • 3. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK, Hanwell MA, Satchell PM, Handelsman DJ, Turtle JR.
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [Abstract] [Full Text] [Related]

  • 4. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 5. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
    Horie S, Nagai H, Yuuki T, Narita Y, Tsuda Y, Nakajima T, Nakamura N.
    J Diabetes Complications; 1998 Oct; 12(3):163-9. PubMed ID: 9618072
    [Abstract] [Full Text] [Related]

  • 6. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DC.
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [Abstract] [Full Text] [Related]

  • 7. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS, Hohman TC, Millen J.
    J Med Chem; 1994 Jun 24; 37(13):2043-58. PubMed ID: 8027986
    [Abstract] [Full Text] [Related]

  • 8. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
    Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D.
    J Med Chem; 1984 Mar 24; 27(3):255-6. PubMed ID: 6422042
    [No Abstract] [Full Text] [Related]

  • 9. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor.
    Dvornik E, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO.
    Science; 1973 Dec 14; 182(4117):1146-8. PubMed ID: 4270794
    [Abstract] [Full Text] [Related]

  • 10. Reduced anterograde and retrograde accumulation of axonally transported phosphofructokinase in streptozotocin-diabetic rats: effects of insulin and the aldose reductase inhibitor 'Statil'.
    Willars GB, Calcutt NA, Tomlinson DR.
    Diabetologia; 1987 Apr 14; 30(4):239-43. PubMed ID: 2439402
    [Abstract] [Full Text] [Related]

  • 11. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
    Lou MF, Dickerson JE, Chandler ML, Brazzell RK, York BM.
    J Ocul Pharmacol; 1989 Apr 14; 5(3):233-40. PubMed ID: 2516529
    [Abstract] [Full Text] [Related]

  • 12. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts].
    Ono H, Nozawa Y, Hayano S.
    Nippon Ganka Gakkai Zasshi; 1982 Apr 14; 86(9):1343-50. PubMed ID: 6818854
    [No Abstract] [Full Text] [Related]

  • 13. Potential aldose reductase inhibitors: 1,2,4-triazolidine-3,5-diones and 2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione .
    Hall IH, Izydore RA, Simlot R, Wong OT.
    Experientia; 1992 Apr 15; 48(4):383-6. PubMed ID: 1582496
    [Abstract] [Full Text] [Related]

  • 14. Spiro hydantoin aldose reductase inhibitors.
    Sarges R, Schnur RC, Belletire JL, Peterson MJ.
    J Med Chem; 1988 Jan 15; 31(1):230-43. PubMed ID: 3121857
    [Abstract] [Full Text] [Related]

  • 15. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH, Ross IS.
    Br J Exp Pathol; 1988 Oct 15; 69(5):697-702. PubMed ID: 3143396
    [Abstract] [Full Text] [Related]

  • 16. The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
    Poulsom R, Mirrlees DJ, Earl DC, Heath H.
    Exp Eye Res; 1983 May 15; 36(5):751-60. PubMed ID: 6406254
    [Abstract] [Full Text] [Related]

  • 17. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C, Dvornik D.
    Proc Soc Exp Biol Med; 1986 Sep 15; 182(4):505-10. PubMed ID: 3090558
    [Abstract] [Full Text] [Related]

  • 18. Glutathione depletion in the lens of galactosemic and diabetic rats.
    Lou MF, Dickerson JE, Garadi R, York BM.
    Exp Eye Res; 1988 Apr 15; 46(4):517-30. PubMed ID: 3133235
    [Abstract] [Full Text] [Related]

  • 19. Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors.
    Kador PF, Akagi Y, Kinoshita JH.
    Diabet Med; 1985 May 15; 2(3):194-6. PubMed ID: 2952419
    [No Abstract] [Full Text] [Related]

  • 20. Aldose reductase in diabetic complications of the eye.
    Kinoshita JH, Fukushi S, Kador P, Merola LO.
    Metabolism; 1979 Apr 15; 28(4 Suppl 1):462-9. PubMed ID: 45423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.